About Seattle Genetics (NASDAQ:SGEN)
Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors. In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma. Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SGEN
CUSIP81257810
Phone425-527-4000
Debt
Debt-to-Equity RatioN/A
Current Ratio3.45%
Quick Ratio3.09%
Price-To-Earnings
Trailing P/E Ratio-56.59
Forward P/E Ratio-32.13
P/E GrowthN/A
Sales & Book Value
Annual Sales$482.25 million
Price / Sales16.33
Cash FlowN/A
Price / CashN/A
Book Value$4.71 per share
Price / Book10.57
Profitability
EPS (Most Recent Fiscal Year)($0.88)
Net Income$-125,530,000.00
Net Margins-26.03%
Return on Equity-32.49%
Return on Assets-24.96%
Miscellaneous
Employees1,100
Outstanding Shares158,160,000
Seattle Genetics (NASDAQ:SGEN) Frequently Asked Questions
What is Seattle Genetics' stock symbol?
Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN."
How were Seattle Genetics' earnings last quarter?
Seattle Genetics (NASDAQ:SGEN) released its quarterly earnings results on Tuesday, February, 6th. The biotechnology company reported ($0.41) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.02. The biotechnology company earned $129.61 million during the quarter, compared to analysts' expectations of $123.99 million. Seattle Genetics had a negative return on equity of 32.49% and a negative net margin of 26.03%. The firm's revenue was up 23.1% compared to the same quarter last year. During the same period last year, the business posted ($0.39) earnings per share. View Seattle Genetics' Earnings History.
When is Seattle Genetics' next earnings date?
What price target have analysts set for SGEN?
17 equities research analysts have issued 1-year price targets for Seattle Genetics' stock. Their predictions range from $48.00 to $75.00. On average, they expect Seattle Genetics' share price to reach $63.7143 in the next twelve months. View Analyst Ratings for Seattle Genetics.
What are Wall Street analysts saying about Seattle Genetics stock?
Here are some recent quotes from research analysts about Seattle Genetics stock:
- 1. According to Zacks Investment Research, "Seattle Genetics' dependence on one product – Adcetris– for growth has its inherent risks. The recent label expansion of Merck’s Keytruda in the lymphoma indication is likely to increase competition. Though the company has multiple candidates in its pipeline, most of them are in early stages of development. However, efforts to expand Adcetris’s label is encouraging. The label expansion in pcALCL, CD30-expressing MF and T-cell lymphoma will boost sales. The company’s collaboration with Takeda for the global development and commercialization of Adcetris is encouraging. Meanwhile, the company’s shares have underperformed the industry in the past year. Estimates movement remains mixed ahead of Q1 results. Seattle Genetics has a mixed record of earnings surprises in the recent quarters." (4/23/2018)
- 2. Cann analysts commented, "The PDUFA date for this approval was May 1, 2018; therefore, the approval is six weeks earlier than we had expected. Our outlook for Adcetris has it being launched in the frontline setting in 2019. However, based on the timing of this approval, we believe Adcetris could be launched in the frontline Hodgkin’s lymphoma setting before year- end 2018. Not only is the impact from a launch in this setting in the near-term not in our estimates, but it is also not in the company’s guidance. This could lead to an increase in estimates for H2 2018." (3/20/2018)
- 3. HC Wainwright analysts commented, "to Approval on June 25 PDUFA; Raise PT to $31 Stock Data 02/06/2018 Price $10.79 Exchange NASDAQ Price Target $31.00 52-Week High $27.79 52-Week Low $9.88 Enterprise Value (M) $282.5 Market Cap (M) $457 Public Market Float (M) 23.8 Shares Outstanding (M) 42.4 3 Month Avg Volume 1,154,580 Short Interest (M) 10.70 Shares Outstanding (M): Figure shown is as of November 2, 2017. Balance Sheet Metrics Cash (M) $199.4 Total Debt (M) $24.9 Total Cash/Share $4.70 Book Value/Share $3.55 Cash (M): Amount shown is as of September 30, 2017. EPS Diluted Full Year – Dec 2016A 2017E 2018E 1Q (0.66) (0.93)A (0.79) 2Q (0.87) (0.78)A (0.82) 3Q (0.41) (0.85)A (0.76) 4Q (1.04) (0.83) (0.75) FY (3.00) (3.10) (3.11) Revenue ($M) Full Year – Dec 2016A 2017E 2018E 1Q 5.8 7.5A 0.6 2Q 9.1 1.3A 0.7 3Q 16.0 0.6A 1.2 4Q 10.7 0.8 1.8 FY 41.8 10.1 4.3 30 25 20 15 10 5 FEB- 17 J UN- 17 OCT- 17 FEB- 18 6 5 4 3 2 1 0 Vol. (mil) Price Manufacturing overhang lifted with VAI status at McPherson site." (2/7/2018)
- 4. JPMorgan Chase analysts commented, "Forecasts; We Expect Shares to Be Pressured Monday morning, ViewRay announced preliminary 2017 revenue of $34M and 4Q17 orders of $34M. Both metrics were significantly below our expectations. With so much investor focus on system sales and conversion to revenue, we expect VRAY to trade off today. The company recognized revenue on 4 MRIdian Linac Systems in the quarter. For the full year, VRAY announced total revenue of $34M. We had modeled $42.5M in revenue for the full year. Management noted that revenue recognition was delayed on one of the 5 systems shipped or installed in the quarter. That delay should result in $7M in revenue recognized in a later period. Investors have been eager to see backlog convert to revenue and this miss is likely to disappoint. In the quarter, VRAY received $34M in new MRIdian Linac System orders, less than the $48M we had forecasted. That order number is lower the company’s orders in the second quarter and likely does not demonstrate enough of an uptick in momentum from the $29.9M order reported in 3Q." (1/9/2018)
Who are some of Seattle Genetics' key competitors?
Some companies that are related to Seattle Genetics include Novozymes (NVZMY), bluebird bio (BLUE), AveXis (AVXS), Qiagen (QGEN), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Spark Therapeutics (ONCE), arGEN-X BV (ARGX), China Biologic Products (CBPO), Halozyme (HALO), CRISPR Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Sangamo Therapeutics (SGMO) and Repligen (RGEN).
Who are Seattle Genetics' key executives?
Seattle Genetics' management team includes the folowing people:
- Dr. Clay B. Siegall, Co-Founder, Chairman, Pres & CEO (Age 57)
- Mr. Todd E. Simpson, CFO & Principal Accounting Officer (Age 57)
- Dr. Vaughn B. Himes Ph.D., Chief Technology Officer (Age 57)
- Dr. Jonathan G. Drachman, Chief Medical Officer and Exec. VP of R&D (Age 56)
- Ms. Jean I. Liu J.D., M.S., Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec. (Age 50)
Has Seattle Genetics been receiving favorable news coverage?
Media stories about SGEN stock have been trending somewhat negative this week, Accern reports. The research group rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Seattle Genetics earned a media sentiment score of -0.06 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 44.77 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
How do I buy shares of Seattle Genetics?
Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Seattle Genetics' stock price today?
One share of SGEN stock can currently be purchased for approximately $49.80.
How big of a company is Seattle Genetics?
Seattle Genetics has a market capitalization of $7.86 billion and generates $482.25 million in revenue each year. The biotechnology company earns $-125,530,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. Seattle Genetics employs 1,100 workers across the globe.
How can I contact Seattle Genetics?
Seattle Genetics' mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected]
MarketBeat Community Rating for Seattle Genetics (SGEN)
MarketBeat's community ratings are surveys of what our community members think about Seattle Genetics and other stocks. Vote "Outperform" if you believe SGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Seattle Genetics (NASDAQ:SGEN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
17 Wall Street analysts have issued ratings and price targets for Seattle Genetics in the last 12 months. Their average twelve-month price target is $63.7143, suggesting that the stock has a possible upside of 27.94%. The high price target for SGEN is $75.00 and the low price target for SGEN is $48.00. There are currently 8 hold ratings and 9 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Hold | Hold |
| Consensus Rating Score: | 2.53 | 2.56 | 2.45 | 2.33 |
| Ratings Breakdown: | 0 Sell Rating(s)
8 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
8 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
11 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
10 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $63.7143 | $64.40 | $63.20 | $61.0667 |
| Price Target Upside: | 27.94% upside | 19.48% upside | 15.58% upside | 2.09% downside |
Seattle Genetics (NASDAQ:SGEN) Consensus Price Target History
Seattle Genetics (NASDAQ:SGEN) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Seattle Genetics (NASDAQ:SGEN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Seattle Genetics (NASDAQ SGEN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 33.80%
Institutional Ownership Percentage: 93.03%
Seattle Genetics (NASDAQ SGEN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/9/2018 | Clay B. Siegall | Insider | Sell | 18,832 | $50.52 | $951,392.64 | |  |
| 3/15/2018 | Vaughn B. Himes | Insider | Sell | 5,000 | $58.12 | $290,600.00 | | |
| 3/9/2018 | Clay B. Siegall | CEO | Sell | 18,832 | $57.32 | $1,079,450.24 | | |
| 3/5/2018 | Jonathan G. Drachman | CMO | Sell | 10,457 | $52.83 | $552,443.31 | | |
| 2/9/2018 | Clay B. Siegall | Insider | Sell | 18,832 | $49.75 | $936,892.00 | | |
| 2/1/2018 | Bros. Advisors Lp Baker | Director | Buy | 3,846,153 | $52.00 | $199,999,956.00 | | |
| 1/11/2018 | Clay B. Siegall | Insider | Sell | 18,832 | $51.71 | $973,802.72 | | |
| 12/11/2017 | Clay B. Siegall | Insider | Sell | 18,832 | $55.40 | $1,043,292.80 | | |
| 12/4/2017 | Eric Dobmeier | COO | Sell | 3,729 | $58.75 | $219,078.75 | | |
| 11/30/2017 | Vaughn B. Himes | Insider | Sell | 10,000 | $59.97 | $599,700.00 | | |
| 11/17/2017 | Eric Dobmeier | COO | Sell | 35,000 | $58.25 | $2,038,750.00 | | |
| 11/15/2017 | Eric Dobmeier | COO | Sell | 9,600 | $57.80 | $554,880.00 | | |
| 11/15/2017 | Marc E. Lippman | Director | Sell | 3,000 | $58.07 | $174,210.00 | | |
| 11/10/2017 | Clay B. Siegall | Insider | Sell | 18,832 | $58.00 | $1,092,256.00 | | |
| 11/1/2017 | Todd E. Simpson | CFO | Sell | 39,385 | $60.91 | $2,398,940.35 | | |
| 10/11/2017 | Clay B Siegall | Insider | Sell | 18,832 | $61.18 | $1,152,141.76 | | |
| 9/11/2017 | Clay B. Siegall | Insider | Sell | 18,832 | $53.49 | $1,007,323.68 | | |
| 9/8/2017 | Vaughn B. Himes | Insider | Sell | 10,000 | $53.22 | $532,200.00 | | |
| 9/6/2017 | Darren S. Cline | EVP | Sell | 5,024 | $51.94 | $260,946.56 | | |
| 9/6/2017 | Todd E. Simpson | CFO | Sell | 9,638 | $52.00 | $501,176.00 | | |
| 8/31/2017 | Darren S. Cline | EVP | Sell | 7,569 | $52.51 | $397,448.19 | | |
| 8/31/2017 | Eric Dobmeier | COO | Sell | 25,000 | $52.24 | $1,306,000.00 | | |
| 8/28/2017 | Clay B. Siegall | CEO | Sell | 25,506 | $47.89 | $1,221,482.34 | | |
| 8/28/2017 | Darren S. Cline | EVP | Sell | 1,788 | $47.89 | $85,627.32 | | |
| 8/28/2017 | Eric Dobmeier | COO | Sell | 5,343 | $47.89 | $255,876.27 | | |
| 8/28/2017 | Jonathan G. Drachman | CMO | Sell | 8,502 | $47.89 | $407,160.78 | | |
| 8/28/2017 | Todd E. Simpson | CFO | Sell | 4,937 | $47.89 | $236,432.93 | | |
| 8/28/2017 | Vaughn B. Himes | Insider | Sell | 6,377 | $47.89 | $305,394.53 | | |
| 8/24/2017 | Jonathan G. Drachman | CMO | Sell | 10,000 | $47.54 | $475,400.00 | | |
| 8/7/2017 | Clay B. Siegall | Insider | Sell | 10,413 | $48.91 | $509,299.83 | | |
| 8/7/2017 | Darren S. Cline | EVP | Sell | 6,000 | $49.19 | $295,140.00 | | |
| 7/27/2017 | Jonathan G. Drachman | CMO | Sell | 10,000 | $54.54 | $545,400.00 | | |
| 7/5/2017 | Clay B. Siegall | CEO | Sell | 10,423 | $51.98 | $541,787.54 | | |
| 6/22/2017 | Jonathan G Drachman | CMO | Sell | 10,000 | $64.01 | $640,100.00 | 125,204 | |
| 6/5/2017 | Clay B. Siegall | Insider | Sell | 10,423 | $65.21 | $679,683.83 | | |
| 4/5/2017 | Clay B Siegall | Insider | Sell | 14,465 | $62.99 | $911,150.35 | 646,858 | |
| 3/31/2017 | Vaughn B Himes | Insider | Sell | 10,000 | $62.75 | $627,500.00 | 161,283 | |
| 3/6/2017 | Clay B Siegall | CEO | Sell | 14,465 | $68.04 | $984,198.60 | 646,858 | |
| 2/6/2017 | Clay B Siegall | Insider | Sell | 14,465 | $61.54 | $890,176.10 | 640,477 | |
| 1/6/2017 | Clay B. Siegall | Insider | Sell | 14,465 | $57.89 | $837,378.85 | | |
| 12/13/2016 | Darren S. Cline | EVP | Sell | 10,000 | $63.38 | $633,800.00 | | |
| 12/8/2016 | Eric Dobmeier | COO | Sell | 12,500 | $65.92 | $824,000.00 | | |
| 12/7/2016 | Vaughn B. Himes | Insider | Sell | 30,000 | $65.32 | $1,959,600.00 | | |
| 11/8/2016 | Felix Baker | Director | Buy | 382,500 | $59.36 | $22,705,200.00 | | |
| 11/7/2016 | Clay B. Siegall | CEO | Sell | 14,465 | $58.43 | $845,189.95 | | |
| 11/7/2016 | Marc E. Lippman | Director | Sell | 1,000 | $57.75 | $57,750.00 | | |
| 11/3/2016 | Felix Baker | Director | Buy | 1,030,629 | $56.13 | $57,849,205.77 | | |
| 11/1/2016 | Jonathan G. Drachman | CMO | Sell | 3,418 | $51.74 | $176,847.32 | | |
| 10/6/2016 | Clay B. Siegall | Insider | Sell | 14,465 | $54.41 | $787,040.65 | | |
| 9/22/2016 | Jonathan G Drachman | CMO | Sell | 2,249 | $56.75 | $127,630.75 | 115,504 | |
| 9/14/2016 | Eric Dobmeier | COO | Sell | 22,918 | $54.04 | $1,238,488.72 | | |
| 9/13/2016 | Felix Baker | Director | Buy | 447,311 | $50.71 | $22,683,140.81 | | |
| 9/8/2016 | Clay B. Siegall | Insider | Sell | 31,269 | $50.08 | $1,565,951.52 | | |
| 9/8/2016 | Felix Baker | Director | Buy | 414,016 | $48.43 | $20,050,794.88 | | |
| 8/23/2016 | Eric Dobmeier | COO | Sell | 12,589 | $48.00 | $604,272.00 | | |
| 8/22/2016 | Clay B. Siegall | Insider | Sell | 23,381 | $46.59 | $1,089,320.79 | | |
| 8/22/2016 | Eric Dobmeier | COO | Sell | 5,411 | $46.59 | $252,098.49 | | |
| 8/22/2016 | Vaughn B. Himes | EVP | Sell | 3,991 | $46.59 | $185,940.69 | | |
| 8/8/2016 | Clay B. Siegall | Insider | Sell | 11,660 | $47.19 | $550,235.40 | | |
| 7/27/2016 | Clay B. Siegall | Insider | Sell | 4,042 | $45.20 | $182,698.40 | | |
| 7/6/2016 | Clay B. Siegall | CEO | Sell | 7,618 | $40.56 | $308,986.08 | | |
| 6/6/2016 | Clay B Siegall | CEO | Sell | 22,083 | $43.59 | $962,597.97 | 566,538 | |
| 6/2/2016 | Darren S Cline | EVP | Sell | 3,366 | $42.07 | $141,607.62 | 42,747 | |
| 5/27/2016 | Clay B Siegall | CEO | Sell | 48,660 | $40.41 | $1,966,350.60 | 563,883 | |
| 5/24/2016 | Clay B Siegall | CEO | Sell | 8,400 | $40.09 | $336,756.00 | 562,815 | |
| 5/23/2016 | Clay B Siegall | CEO | Sell | 6,700 | $40.12 | $268,804.00 | 562,815 | |
| 5/17/2016 | Clay B Siegall | CEO | Sell | 7,618 | $35.16 | $267,848.88 | 563,733 | |
| 4/25/2016 | Clay B Siegall | CEO | Sell | 800 | $40.00 | $32,000.00 | 556,915 | |
| 4/5/2016 | Clay B Siegall | CEO | Sell | 7,618 | $36.12 | $275,162.16 | 563,733 | |
| 3/22/2016 | Clay B Siegall | CEO | Sell | 15,236 | $35.52 | $541,182.72 | 560,397 | |
| 3/21/2016 | Clay B Siegall | CEO | Sell | 4,282 | $35.01 | $149,912.82 | 560,397 | |
| 3/17/2016 | Felix Baker | Director | Buy | 124,065 | $31.85 | $3,951,470.25 | 38,783,387 | |
| 3/16/2016 | Felix Baker | Director | Buy | 1,349,237 | $32.10 | $43,310,507.70 | 107,511 | |
| 3/15/2016 | Felix Baker | Director | Buy | 661,093 | $32.08 | $21,207,863.44 | 38,671,506 | |
| 3/14/2016 | Felix Baker | Director | Buy | 118,941 | $33.77 | $4,016,637.57 | 38,671,506 | |
| 3/11/2016 | Felix Baker | Director | Buy | 694,666 | $32.46 | $22,548,858.36 | 37,454,776 | |
| 3/8/2016 | Felix Baker | Director | Buy | 502,523 | $22.66 | $11,387,171.18 | 107,511 | |
| 3/2/2016 | Felix Baker | Director | Buy | 675,922 | $31.77 | $21,474,041.94 | 107,511 | |
| 3/1/2016 | Felix Baker | Director | Buy | 24,200 | $31.24 | $756,008.00 | 107,511 | |
| 2/29/2016 | Felix Baker | Director | Buy | 251,722 | $30.39 | $7,649,831.58 | 107,511 | |
| 2/26/2016 | Felix Baker | Director | Buy | 314,508 | $29.55 | $9,293,711.40 | | |
| 2/22/2016 | Felix Baker | Director | Buy | 1,001,471 | $29.63 | $29,673,585.73 | | |
| 2/17/2016 | Felix Baker | Director | Buy | 1,269,147 | $30.43 | $38,620,143.21 | | |
| 2/12/2016 | John A. Orwin | Director | Buy | 2,000 | $28.33 | $56,660.00 | | |
| 12/15/2015 | Vaughn B. Himes | EVP | Sell | 40,500 | $39.94 | $1,617,570.00 | 76,212 | |
| 12/3/2015 | Clay B. Siegall | CEO | Sell | 3,720 | $39.99 | $148,762.80 | 556,115 | |
| 11/20/2015 | Felix Baker | Director | Buy | 329,358 | $43.94 | $14,471,990.52 | 107,504 | |
| 11/17/2015 | Clay B Siegall | CEO | Sell | 87,473 | $45.40 | $3,971,274.20 | 556,115 | |
| 11/11/2015 | Darren S Cline | SVP | Sell | 5,769 | $45.68 | $263,527.92 | 37,713 | |
| 11/10/2015 | Felix Baker | Director | Buy | 934,624 | $42.95 | $40,142,100.80 | 107,504 | |
| 11/9/2015 | Felix Baker | Director | Buy | 507,300 | $43.76 | $22,199,448.00 | 107,504 | |
| 11/6/2015 | Eric Dobmeier | COO | Sell | 17,452 | $42.50 | $741,710.00 | 80,888 | |
| 11/6/2015 | Felix Baker | Director | Buy | 417,924 | $41.94 | $17,527,732.56 | 107,504 | |
| 11/5/2015 | David W Gryska | Director | Sell | 10,000 | $43.57 | $435,700.00 | 23,950 | |
| 11/4/2015 | Clay B. Siegall | CEO | Sell | 3,718 | $43.14 | $160,394.52 | 643,588 | |
| 10/5/2015 | Clay B. Siegall | CEO | Sell | 3,718 | $41.30 | $153,553.40 | 611,323 | |
| 9/3/2015 | Clay B. Siegall | CEO | Sell | 3,718 | $40.12 | $149,166.16 | 611,323 | |
| 8/20/2015 | Clay B. Siegall | CEO | Sell | 31,754 | $42.02 | $1,334,303.08 | 611,323 | |
| 8/20/2015 | Darren S. Cline | SVP | Sell | 2,231 | $42.02 | $93,746.62 | 43,482 | |
| 8/20/2015 | Eric Dobmeier | COO | Sell | 8,548 | $42.02 | $359,186.96 | 98,340 | |
| 8/20/2015 | Jonathan G. Drachman | CMO | Sell | 4,462 | $42.02 | $187,493.24 | 82,724 | |
| 8/20/2015 | Todd E. Simpson | CFO | Sell | 5,825 | $42.02 | $244,766.50 | 179,874 | |
| 8/20/2015 | Vaughn B. Himes | EVP | Sell | 5,997 | $42.02 | $251,993.94 | 76,212 | |
| 7/6/2015 | Clay B Siegall | CEO | Sell | 3,718 | $46.94 | $174,522.92 | | |
| 6/3/2015 | Clay B Siegall | CEO | Sell | 3,718 | $45.72 | $169,986.96 | | |
| 5/21/2015 | Felix Baker | Director | Buy | 950,886 | $42.49 | $40,403,146.14 | | |
| 5/8/2015 | Eric Dobmeier | COO | Sell | 17,074 | $40.38 | $689,448.12 | | |
| 5/7/2015 | Felix Baker | Director | Buy | 1,032,664 | $35.56 | $36,721,531.84 | | |
| 3/10/2015 | Felix Baker | Director | Buy | 285,036 | $34.66 | $9,879,347.76 | | |
| 3/9/2015 | Felix Baker | Director | Buy | 275,717 | $34.66 | $9,556,351.22 | | |
| 3/4/2015 | Felix Baker | Director | Buy | 448,841 | $34.84 | $15,637,620.44 | | |
| 2/25/2015 | Felix Baker | Director | Buy | 281,115 | $33.92 | $9,535,420.80 | | |
| 1/6/2015 | Clay B Siegall | CEO | Sell | 16,804 | $31.80 | $534,367.20 | | |
| 12/16/2014 | Felix Baker | Director | Buy | 2,883,378 | $31.86 | $91,864,423.08 | | |
| 12/10/2014 | Felix Baker | Director | Buy | 1,247,896 | $33.82 | $42,203,842.72 | | |
| 12/9/2014 | Felix Baker | Director | Buy | 128,430 | $34.16 | $4,387,168.80 | | |
| 12/8/2014 | Felix Baker | Director | Buy | 465,316 | $32.93 | $15,322,855.88 | | |
| 11/12/2014 | Vaughn B Himes | EVP | Sell | 10,000 | $37.52 | $375,200.00 | | |
| 11/10/2014 | Felix Baker | Director | Buy | 1,653,925 | $34.56 | $57,159,648.00 | | |
| 9/4/2014 | Clay B Siegall | CEO | Sell | 5,600 | $42.54 | $238,224.00 | | |
| 8/12/2014 | Clay B Siegall | CEO | Sell | 11,200 | $40.38 | $452,256.00 | | |
| 8/11/2014 | Clay B Siegall | CEO | Sell | 2,700 | $40.05 | $108,135.00 | | |
| 6/13/2014 | Felix Baker | Director | Buy | 216,595 | $39.92 | $8,646,472.40 | | |
| 6/10/2014 | Clay B Siegall | CEO | Sell | 11,200 | $40.14 | $449,568.00 | | |
| 6/9/2014 | Felix Baker | Director | Buy | 546,252 | $38.16 | $20,844,976.32 | | |
| 6/4/2014 | Felix Baker | Director | Buy | 281,963 | $34.86 | $9,829,230.18 | | |
| 5/16/2014 | Felix Baker | Director | Buy | 189,611 | $34.07 | $6,460,046.77 | 76,997 | |
| 4/3/2014 | Clay Siegall | CEO | Sell | 5,600 | $43.34 | $242,704.00 | 955,696 | |
| 2/18/2014 | Clay Siegall | CEO | Sell | 100,000 | $51.97 | $5,197,000.00 | 955,696 | |
| 1/21/2014 | Eric Dobmeier | COO | Sell | 56,010 | $47.92 | $2,683,999.20 | 77,833 | |
| 1/16/2014 | Jonathan Drachman | CMO | Sell | 1,201 | $45.75 | $54,945.75 | 49,911 | |
| 12/16/2013 | Felix Baker | Director | Buy | 407,078 | $39.66 | $16,144,713.48 | 76,997 | |
| 12/5/2013 | Felix Baker | Director | Buy | 1,005,901 | $43.19 | $43,444,864.19 | 76,997 | |
| 10/1/2013 | Clay B Siegall | CEO | Sell | 2,000 | $43.87 | $87,740.00 | | |
| 9/10/2013 | Eric Dobmeier | COO | Sell | 42,000 | $46.40 | $1,948,800.00 | | |
| 9/5/2013 | Eric Dobmeier | COO | Sell | 75,000 | $42.64 | $3,198,000.00 | | |
| 9/3/2013 | Clay B Siegall | CEO | Sell | 102,000 | $43.90 | $4,477,800.00 | | |
| 9/3/2013 | David W Gryska | Director | Sell | 10,000 | $42.48 | $424,800.00 | | |
| 8/27/2013 | Todd Simpson | CFO | Sell | 37,763 | $41.45 | $1,565,276.35 | 155,395 | |
| 8/19/2013 | Clay Siegall | CEO | Sell | 7,653 | $40.91 | $313,084.23 | 1,124,558 | |
| 8/19/2013 | Eric Dobmeier | COO | Sell | 3,328 | $40.91 | $136,148.48 | 127,620 | |
| 8/19/2013 | Vaughn Himes | EVP | Sell | 1,736 | $40.91 | $71,019.76 | 46,307 | |
| 8/1/2013 | Clay B Siegall | CEO | Sell | 2,000 | $40.03 | $80,060.00 | | |
| 7/12/2013 | Todd E Simpson | CFO | Sell | 92,527 | $37.45 | $3,465,136.15 | | |
| 7/1/2013 | Clay B Siegall | CEO | Sell | 2,000 | $32.59 | $65,180.00 | | |
| 6/14/2013 | Srinivas Akkaraju | Director | Sell | 5,000 | $32.75 | $163,750.00 | | |
| 6/13/2013 | Vaughn B Himes | EVP | Sell | 10,000 | $32.11 | $321,100.00 | | |
| 6/3/2013 | Clay B Siegall | CEO | Sell | 2,000 | $33.88 | $67,760.00 | | |
| 5/10/2013 | Srinivas Akkaraju | Director | Sell | 17,500 | $37.17 | $650,475.00 | | |
| 3/6/2013 | Eric Dobmeier | COO | Sell | 100,000 | $29.68 | $2,968,000.00 | | |
| 2/25/2013 | David W Gryska | Director | Sell | 10,000 | $27.17 | $271,700.00 | | |
| 2/1/2013 | Clay B Siegall | CEO | Sell | 2,000 | $29.61 | $59,220.00 | | |
| 1/15/2013 | Thomas C Reynolds | Insider | Sell | 125,079 | $28.00 | $3,502,212.00 | | |
| 11/1/2012 | Clay B Siegall | CEO | Sell | 8,250 | $25.51 | $210,457.50 | | |
| 9/4/2012 | Clay B Siegall | CEO | Sell | 8,250 | $26.54 | $218,955.00 | | |
(Data available from 1/1/2013 forward)
Seattle Genetics (NASDAQ SGEN) News Headlines
| Source: |
|
Seattle Genetics (NASDAQ:SGEN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Seattle Genetics (NASDAQ:SGEN) Income Statement, Balance Sheet and Cash Flow Statement
Seattle Genetics (NASDAQ SGEN) Stock Chart for Monday, April, 23, 2018
Loading chart…
